World Health Organization Sounds Concern Over Severe Scarcity of Obesity Medications

Fewer than a tenth of patients eligible to benefit from GLP-1 drugs like Wegovy have access to them, warns the WHO as it publishes its initial advice on the drugs.

Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for broader and more equitable availability to these injectable treatments.

Per estimates, over two billion are projected to be living with obesity by 2030 if no action is taken.

"Our new guidelines affirms that excess weight is a lifelong illness that can be managed with comprehensive and ongoing support," said its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are major barriers to universal access to the treatments that can aid individuals in losing considerable weight, says the organization.

Weight-Loss Drug Scarcity

Despite the current most optimistic outlook, the manufacturing of such drugs would only suffice for approximately 100 million people – under 10% of eligible patients, per the WHO.

The guideline urges countries and companies to widen availability, through strategies including licensing agreements.

The intellectual property rights on a key compound – the core component of a leading brand – is due to expire in several nations in 2026.

The Way Obesity Injections Work

GLP-1 drugs mimick a natural hormone to reduce digestion speed, reduce hunger and enhance the sense of being full so users reduce food intake.

Individuals usually start to lose weight after several weeks of commencing the once-weekly jabs.

Studies indicates users may see weight return within a year of stopping the drug, because their typical food cravings come back.

To be carrying excess weight raises your likelihood for contracting health problems, like type 2 diabetes, heart disease, brain attack, and specific malignancies.

Obesity impacts individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.